(b) in agreement with the National Security Authorities (NSAs)/Designated Security Authorities (DSAs) of member nations concerned, assist and give guidance to other NSAs/DSAs in the implementation of NATO security policies and directives in connection with the activities of NPLOs;

Annex C to Directive 92/51/EEC shall be amended as follows:1.

In patients taking any type of nonsteroidal antiinflammatory drug, the use of a nitrovasodilator or antisecretory therapy was independently associated with a decreased risk of bleeding.

Results In the week before admission, 520 (46.3 percent) of the patients with bleeding had taken a nonsteroidal antiinflammatory drug other than low-dose aspirin, 120 (10.7 percent) had taken low-dose aspirin (300 mg per day), 60 (5.3 percent) a nitrovasodilator, and 135 (12.0 percent) an antisecretory agent such as a histamine H2-receptor antagonist or a proton-pump inhibitor.

In multivariate models that adjusted for age, sex, and clinical risk factors, the use of a nonsteroidal antiinflammatory drug other than low-dose aspirin was independently associated with an increased risk of bleeding from a peptic ulcer (odds ratio, 7.4; 95 percent confidence interval, 4.5 to 12.0), as was the use of low-dose aspirin alone (odds ratio, 2.4; 95 percent confidence interval, 1.8 to 3.3).

NSAP Adresses

NSAP Addressing

called NSAP address

NSAP Address Structure.

NSAP Address Structure

Parameter type = Calling NSAP

NSAP addresses are restricted to the form defined in;

The components of the NSAP address are defined below:

The resulting NSAP address structure is illustrated below.

Parameter type = Called NSAP

NOTE The called NSAP address may optionally also be validated against a list of (typically of one item) valid local NSAP addresses for the system.

the calling NSAP address of the N-Connect-Indication is the same as the called NSAP address of the outstanding N-Connect-Request;

A conforming implementation shall use NSAP addresses as defined in Annex C.

NSAP Address Structure.................................................

The calling NSAP address encoded as described above in an INCOMING CALL packet shall be validated against a local list of valid remote NSAP addresses for the system.

The structure of the NSAP addresses follows that defined in ISO/IEC 8348 Annex A [Reference 10], as illustrated below.

The calling and called NSAP addresses shall be encoded using the preferred binary encoding defined in ISO/IEC 8348 Annex A [Reference 10].

the calling NSAP address of the outstanding N-Connect-Request is greater than the called NSAP address of the outstanding N-Connect-Request, the comparison being made on the bit strings formed by the preferred binary encoding of each NSAP address, as defined in ISO/IEC 8348 Annex A [Reference 10] (a string shall be considered greater than any of its proper initial substrings, e.g. '8800'H > '88'H).

of the network service parameters for which encodings are defined in ISO/IEC 8878 [Reference 12], only the called and calling NSAP addresses (and only in the form defined in) are sent in the CALL REQUEST packet;

The protocols and packet formats defined in this Eurocontrol Standard Document are a compatible subset of those of the ST-ICD with the exception that this Eurocontrol Standard makes more detailed requirements on the use of the X.25 PLP, includes mandatory support of the M-bit and corrects the inconsistent specification of the Authority and Format Identifier (AFI) value in the Network Service Access Point (NSAP) address.

NSAI

Other NSAIDs:

Interaction with NSAIDs has not been suggested.

information of Section 4.5.

Non-steroidal anti-inflammatory drugs (NSAIDs)

Adjustment of dosage of NSAIDs may be needed.

- you are also taking non-steroidal anti-inflammatory drugs (NSAIDs), since both types of

Use of topical NSAIDs may result in keratitis.

Onsior must not be administered in conjunction with other NSAIDs.

Amfenac is a non-steroidal anti-inflammatory drug (NSAID).

NSAIDs and COX-2 inhibitors).

Topical NSAIDs may slow or delay healing.

Formal interaction studies with lansoprazole and NSAIDs have not been conducted.

There were no significant differences between lumiracoxib and NSAIDs.

Benign NSAID-associated gastric and duodenal ulcers:

Non-Steroidal Anti-Inflammatory Drugs (CYP2C9 substrates):

Robenacoxib is a non-steroidal anti-inflammatory drug (NSAID).

There are many sorts of NSAIDs with different durations of activity.

NSAIDs may reduce the effect of diuretics and antihypertensive medicinal products.

Topical NSAIDs should be used with caution in these patients.

Pharmacotherapeutic group: Non-steroidal, anti-inflammatory drug (NSAID)

In patients who continue to take NSAID medication healing is delayed.

NSAIDs may reduce the effect of diuretics and antihypertensive drugs.

Prophylaxis of NSAID-associated gastric and duodenal ulcers in patients requiring continuous NSAID- treatment:

No formal interaction studies with lansoprazole and NSAIDs have been performed.